Novostia

Executive Summary

Novostia is a Swiss medical device company developing the Triflo valve, a next-generation artificial heart valve designed for both aortic and mitral valve replacement. The valve aims to address key limitations of current mechanical and bioprosthetic valves by offering low thrombogenicity (potentially reducing the need for lifelong anticoagulation), lifelong durability (using a novel polymer-based design), and a low acoustic signature (minimizing noise for patients). The device is currently in preclinical development and has not yet received regulatory approval. Founded in 2016 and based in Lausanne, Novostia operates in a large and growing market for heart valve replacement, with significant unmet need for a durable, low-thrombogenicity option. The company's technology has the potential to disrupt the sector if clinical validation is successful. However, as a preclinical-stage company, it faces substantial technical, regulatory, and commercial risks. The path to market will require successful completion of preclinical studies, first-in-human trials, and subsequent regulatory approvals (likely beginning with CE marking in Europe). Funding is a critical near-term catalyst to advance these activities. Overall, Novostia represents a high-risk, high-reward investment opportunity in the cardiovascular device space.

Upcoming Catalysts (preview)

• Q4 2026Series B Financing to Fund First-in-Human Study60% success
• Q2 2027CE Mark Application Submission for Triflo Valve30% success
• Q1 2027Initiation of First-in-Human Clinical Trial40% success